Phase 2 Trial to Test Keytruda, Tomivosertib Combo in Triple-negative Breast Cancers

Phase 2 Trial to Test Keytruda, Tomivosertib Combo in Triple-negative Breast Cancers
An upcoming Phase 2 trial will evaluate a combination of the immunotherapies Keytruda (pembrolizumab) and tomivosertib (eFT508) as a treatment for triple-negative breast cancer patients whose disease has spread to other regions, or metastasized. As part of a new collaboration between eFFECTOR Therapeutics and Merck (known as MSD outside the U.S. and Canada), the trial will test the combination in women who have failed up to two prior treatments. Enrollment is expected to begin in early 2019. "The TNBC trial will expand the current tomivosertib Phase 2 clinical trial program, allowing eFFECTOR to explore a combination with Keytruda for an indication in which neither drug is yet approved," Steve Worland, PhD, president and CEO of eFFECTOR, said in a press release. In an attempt to prevent the immune system from attacking the body's own cells and tissues, immune cells are equipped with a series of checkpoint molecules that prevent them from becoming overactive. Cancer cells often take advantage of this mechanism and produce molecules that activate these checkpoints, preventing immune cells from detecting and eliminating them. Many immune checkpoint inhibitors are already approved for cancer indications, including Opdivo (nivolumab), Keytruda (pembrolizum
Subscribe or to access all post and page content.

One comment

  1. Sheila Stein says:

    I was diagnosed with Tripple Negative almost 3 years ago.Never in my lymph nodes.I was given 12 chemo treatments and radiation.I received my treatment at Fox Chase Cancer Cener.My doctors name was DR. Elias Obeid
    Please keep me informed.Thank you,Sheila Stein

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.